+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07645118

Evaluation of Targeted Brachytherapy Followed by Nivolumab Immunotherapy Before Surgery in Stage IIIII Locally Advanced Rectal Cancer

Led by Dr. Te Vuong · Updated on 2026-10-28

10

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a targeted internal radiation treatment called HDR brachytherapy followed by two doses of the immunotherapy drug Nivolumab before surgery to remove rectal cancer. This Phase II study focuses on patients with locally advanced, mismatch repair proficient rectal cancer to assess safety, feasibility, and potential effectiveness. Participants receive HDR brachytherapy with a total dose of 26 Gy divided into 4 sessions over four days. Starting 7 to 14 days after brachytherapy, they receive up to two intravenous doses of Nivolumab every two weeks. Surgical removal of the tumor through total mesorectal excision is planned 6 to 8 weeks after completing brachytherapy, up to a maximum of 12 weeks. During the study, participants undergo monitoring including assessments of tumor response at surgery approximately 12 weeks after enrollment. Researchers track adverse events from the first treatment through 90 days after the last Nivolumab dose. Feasibility of the treatment sequence is also evaluated. Overall participation lasts about 12 weeks from enrollment to surgery.

CONDITIONS

Brief Title

Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here